|
|||||||||||||||||||||||||||||||
|
SEARCH BY KEYWORD
|
Category: AllShort TakesJune 5, 2009
Highlights
Grace-Marie Turner Recent News Articles and Studies Just Don't Try to Go the European Way Just Don't Try to Go the European Way Although many U.S. reformers praise the health systems of Britain, France, Switzerland, and other European nations, these systems are fraught with problems, writes Turner. They are burdened by cost overruns, and yet they still deny patients the latest care and the choices we take for granted. In France, for example, the government now dictates which doctors and specialists a patient can see. Strict reimbursement schedules in government-controlled systems penalize doctors for performing costly procedures, even when those procedures are clinically determined to be best for the patient. Consequently, many doctors refuse to treat patients with certain illnesses. Maintaining high-quality health care while keeping costs low is no easy task, writes Turner. But the lessons from Europe are clear: When government tries to reduce costs, health care quality and access suffer. Who Will Save Us From Swine Flu? The swine flu outbreak was a vivid reminder of how far we've come in dealing with the threat of viral pandemics, writes Turner. Health authorities responded in record time, limiting the spread of the virus and the loss of life, at least so far. For most people, the availability of antiviral drugs like Tamiflu and Relenza have proven immensely effective in treating the illness, calming fears about the spread of the virus. Researchers are also working hard to develop a vaccine that they hope to have available by this fall. It seems a paradox then that the pharmaceutical industry, which we rely on to develop these medicines, is generally scorned by politicians and even by many citizens. This attitude isn't just disingenuous. . . it's dangerous, writes Turner. The government cannot develop and deliver the drugs we need. In fact, government research makes a significant contribution to the creation of only one in 10 new drugs. Continued progress in medical innovation requires continued investment in new research by private industry. Antivirals can save thousands or even millions of lives in the event of a truly lethal swine flu epidemic, writes Jack Calfee of the American Enterprise Institute. The pharmaceutical industry's ability to develop these essential drugs shows it plays an important role in advancing public health. Battle Will Set Health Policy for Decades The main battle in the health reform debate in Washington is being fought over whether the federal government will set up its own health insurance plan to compete with private companies, writes Turner. Both sides understand that this is the pivot point over how our health sector develops over the next several decades. While there may be initial assurances that the public plan option would operate on a level playing field with private insurance, the government inevitably will use its regulatory, pricing and taxing authority to favor its plan. Government will ration care and services, driving out innovation, competition, and patient-centered quality. There are serious problems of cost, value and access in our health sector, and it is vital to address them. But any health reform proposal to change what needs fixing also must preserve the freedom, innovation, and quality of American medical care that people value. HEALTH CARE REFORMWhat You Don't Know Can Hurt You There is a strong association between educational attainment and health. That's one more reason to empower Americans, not Washington, with greater ownership of their healthcare, writes Miller. We are in the midst of another "historic" healthcare reform debate that again remains prone to focus more narrowly on the objectives of expanding more comprehensive insurance coverage to all Americans, and finding (or at least pretending to find) sufficient additional resources to finance the delivery of even more healthcare services to them. One still hears much more about Washington-determined rules, mandates, spending, and taxes to come than about how individual Americans might be empowered and assisted in taking more ownership of their personal healthcare decisions, such as through improved education, more actionable information resources, shared decision-making tools, and better-targeted incentives. Can we avoid another painfully frustrating lesson in the limits of insurance-coverage expansions and more bloated public budgets alone? A quick trip back to reform school for health policymakers might teach them the value of refocusing on a broader portfolio of private and public investments in the education-related determinants of better lifetime health. Because what we don't know really can hurt us, concludes Miller. Why the Health Care Rush? Democrats are trying to rush the largest entitlement expansion since LBJ into law with a truncated debate and as little public scrutiny as possible, writes The Wall Street Journal. It's not hard to see why Democrats are trying to hew this full-speed-ahead timetable. Their health overhaul will run up a 13-figure price tag at a time when spending and deficits are already at epic levels and hook up the middle class to an intravenous drip of government health subsidies for generations to come. These are not realities that Democrats want the American people to mull over for very long. Better to grab what they will portray as a major domestic achievement while President Obama is at the height of his popularity and before anyone understands what it will mean in practice. STATE ISSUESHealth Insurance Mandates in the States 2009 The number of state mandated health benefits continues to grow -- to 2,133 nationwide, up from 1,961 last year, according to CAHI's annual list of health insurance mandates in each state. The report contains a chart of the mandates with information broken down by state into three categories: types of mandated benefits, providers, and covered populations. Mandated benefits currently increase the cost of coverage from a little less than 20% to perhaps 50%, depending on the state and the specific legislative language. Rhode Island leads the states with 70 mandates, while Idaho has the fewest at 13. Fortunately, there is evidence that some legislators are getting CAHI's message. At least 30 states now require that a mandate's costs be assessed before it is implemented, and at least 10 states provide for mandate-light policies, which allow some individuals to purchase a policy with fewer mandates more tailored to their needs and financial situation. State Employee Health Care as a "Public Plan" Some analysts have suggested that the experience of state governments in fielding a "public plan" for employees that competes with private health plans for the premium dollars of state employees is the proof that public plans can compete fairly and effectively. But the experience of the states provides a good example of a "public plan" only if one is willing to stretch the meaning of a public plan well beyond all recognition, writes Moffit. State employee health plans are really private health plans under contract with state government, and the simple fact that they are self-insured (like many private plans) does not make them public entities. If Congress creates a public plan, it is likely to be too big to fail, as is the case with so many other enterprises, thereby guaranteeing even greater burdens on taxpayers who are already faced with the seemingly insurmountable debt imposed by Social Security, Medicare, and Medicaid. 2009 Survey of Physician Appointment Wait Times This survey offers a snapshot of physician availability in 15 large metropolitan markets with some of the highest physician-to-population ratios in the country. Despite having a high number of physicians per capita, many of these markets are experiencing appointment wait times of 14 days or longer. Boston experiences by far the longest average wait times of any of the 15 metropolitan markets (49.6 days). Long wait times in Boston may be driven in part by the health care reform initiative that was put in place in Massachusetts in 2006. The initiative succeeded in covering many of the state's uninsured patients. However, it has been reported that many patients in Massachusetts are experiencing difficulty in accessing physicians. Survey results support these reports. Long appointment wait times in Boston also may signal what could happen nationally in the event that access to health care is expanded through health care reform. HEALTH CARE COSTSThe Cost Conundrum Gawande uses McAllen, Texas, to provide a compelling account of the forces that are driving up health spending in the United States. McAllen has the lowest per-capita income in the country ($12,000) and the highest per-capita Medicare expenditures ($15,000). And yet there's no evidence that the treatments and technologies available in McAllen are better than those found elsewhere in the country. When you look at the differences in the costs of care you come to realize that we are witnessing a battle for the soul of American medicine, writes Gawande. Somewhere in the United States at this moment, a patient with chest pain, or a tumor, or a cough is seeing a doctor. And the damning question we have to ask is whether the doctor is set up to meet the needs of the patients, first and foremost, or to maximize revenue. Gawande's description of the symptoms -- high spending, low value -- is compelling, but just don't look to him for a cure, writes Joe Antos of the American Enterprise Institute. Gawande recommends "accountable-care organizations" for doctors and hospitals that would promote collaboration, higher quality, and more prevention, while discouraging overtreatment, undertreatment, and "sheer profiteering." But, despite the enthusiasm of experts, ACOs do not exist and it is not clear how they would accomplish what has been promised. What Gawande doesn't say is that we cannot solve our health system problems by top-down solutions that focus solely on the suppliers of health care, writes Antos. If a reformed health system is to succeed, it will have to engage patients to take more responsibility for their health spending decisions. And it will have to respond nimbly to the demands of its customers -- something that is sorely missing today. PRESCRIPTION DRUGSThe End of Medical Miracles? Americans have, at best, a love-hate relationship with the life-sciences industry, writes Troy, former deputy secretary of Health and Human Services. These days, the mere mention of a pharmaceutical manufacturer seems to elicit gut-level hostility. At the same time, Americans are adamant about the need for access to the newest cures and therapies and expect them to emerge for their every ailment -- all of which result from work done primarily by these same companies whose profits make possible the research that allows for such breakthroughs. Attempts to universalize our system and pay for it with cost controls that could stifle innovation contradict their own goal, which is, presumably, better health, writes Troy. One of the greatest threats to our health and continued welfare is that Americans in the present day, and particularly their leaders, are taking for granted the power, potency, and progress flowing from life-saving medical innovations. And in so doing, they may unknowingly prevent the kind of advance that could contribute as vitally to the welfare of the 21st century as the discovery of the antibiotic altered the course of human history for the better in the century just concluded. Upcoming Events The Dollars and Sense of Prevention: A Primer for Health Policy Makers Implementing Comparative Effectiveness Research: Priorities, Methods and Impact Comparative Effectiveness Research around the World The Future of Employer-Provided Health Care The Convergence of Health and Wealth: The Next Frontier Reducing Health Care Costs: Chronic Disease Management for Alcohol and Drug Problems Health Reform: Journalists' Perspectives Health Care Reform Biosimilar Biological Products
Health Policy Matters is a weekly newsletter containing summaries of timely and informative studies and articles on free-market health reform. It features a commentary by Grace-Marie Turner on the major developments and issues of the week as well as summaries of writings by participants in the Health Policy Consensus Group and other articles of interest from the health policy world, plus announcements of coming events. Health Policy Matters is published by the Galen Institute, a not-for-profit public policy organization specializing in information and education on health policy. For more information about the newsletter and our organization, please visit our website at www.galen.org. If you wish to subscribe to this free weekly newsletter, update your address, or be removed from our list, please send an e-mail message to galen@galen.org. The views expressed in this newsletter are the opinions of the authors and do not necessarily reflect the views of the Galen Institute or its directors. |
||||||||||||||||||||||||||||||